Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07291141

A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis

Status
Recruiting
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Mattias Ekstedt · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.

Conditions

Timeline

Start date
2025-12-18
Primary completion
2029-12-01
Completion
2031-12-01
First posted
2025-12-18
Last updated
2025-12-19

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT07291141. Inclusion in this directory is not an endorsement.